Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy aloneMichael Gnant, Torsten O. Nielsen, Christian F. Singer et al.|Annals of Oncology|2013Cited by 403
Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 TrialGeorg Pfeiler, Michael Gnant, Christian Fesl et al.|Journal of Clinical Oncology|2011Cited by 222
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34Rupert Bartsch, Christian F. Singer, Georg Pfeiler et al.|British Journal of Cancer|2021Cited by 16
Abstract P6-10-01: Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34)CF Singer, G Michael, Georg Pfeiler et al.|Cancer Research|2017Cited by 2
Abstract GS6-04: The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2- breast cancer patients from ABCSG 34P Dubsky, Martin Filipits, Christian Fesl et al.|Cancer Research|2018Cited by 2